Overview

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Primary: Effect on HbA1c over 48 weeks in insulin-treated patients with type 2 diabetes Secondary: Effect on glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides - Safety, tolerability
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Rimonabant